NCT02422381View on ClinicalTrials.gov

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 20, 2015

Primary Completion Date

January 9, 2019

Study Completion Date

December 31, 2025

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

MK-3475

Investigational drug.

DRUG

Gemcitabine

Standard care drug.

Trial Locations (2)

97213

Providence Oncology & Hematology Care Clinic - Eastside, Portland

97225

Providence Oncology & Hematology Care Clinic - Westside, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Providence Cancer Center, Earle A. Chiles Research Institute

OTHER

lead

Providence Health & Services

OTHER

NCT02422381 - MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter